Progenics Pharmaceuticals, Inc. (Ta...

Progenics Pharmaceuticals, Inc. (Tarrytown, NY) has reported novel findings from a complet Phase 2 thought of Pro 542, an avenue inhibitor for the treatment of HIV. Previously, the company had reported that single doses of the unsalable article reduced concentrations of HIV in the posterity by 60%-80% in a target population of highly treatment-experienced make liables Now, scientists have place that the magnitude of viral load reductions observ in the